苑东生物(688513)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688513 苑东生物

已收盘 07-25 15:00:00

{"stockData":{"symbol":"688513","market":"SH","secType":"STK","nameCN":"苑东生物","latestPrice":55.61,"timestamp":1753426800000,"preClose":52.2,"halted":0,"volume":6777137,"delay":0,"changeRate":0.0653,"floatShares":177000000,"shares":177000000,"eps":1.2679,"marketStatus":"已收盘","change":3.41,"latestTime":"07-25 15:00:00","open":51.91,"high":57.3,"low":51,"amount":372000000,"amplitude":0.1207,"askPrice":55.7,"askSize":2,"bidPrice":55.61,"bidSize":42,"shortable":0,"etf":0,"ttmEps":1.2679,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":5,"adr":0,"adjPreClose":52.2,"symbolType":"stock_kcb","openAndCloseTimeList":[[1753407000000,1753414200000],[1753419600000,1753426800000]],"highLimit":57.42,"lowLimit":46.98,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":176532256,"isCdr":false,"pbRate":3.55,"roa":"--","peRate":43.859926,"roe":"2.22%","epsLYR":1.36,"committee":0.709273,"marketValue":9817000000,"turnoverRate":0.0384,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-07-28。","afterMarket":{"amount":0,"volume":0,"close":55.61,"buyVolume":0,"sellVolume":200,"time":1753428838020,"indexStatus":"已收盘 07-25 15:30:00","preClose":52.2},"floatMarketCap":9817000000},"requestUrl":"/m/hq/s/688513","defaultTab":"news","newsList":[{"id":"2554716357","title":"华创医药投资观点&研究专题周周谈·第136期：高血压创新药是一笔好生意吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2554716357","media":"华创证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554716357?lang=zh_cn&edition=full","pubTime":"2025-07-26 00:00","pubTimestamp":1753459200,"startTime":"0","endTime":"0","summary":"本周行情回顾本周，中信医药指数上涨1.97%，跑赢沪深300指数0.28个百分点，在中信30个一级行业中排名第19位。本周涨幅前十名股票为海特生物、振东制药、塞力医疗、辰欣药业、仁度生物、康芝药业、易明医药、苑东生物、康泰医学、迈普医学。本周跌幅前十名股票*ST苏吴、永安药业、力生制药、首药控股-U、泽璟制药-U、科兴制药、信立泰、上海谊众、浙江震元、神州细胞。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726164141a4647f7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726164141a4647f7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","688091","688513","688266","159377","600200","688197","688520","BK0239","603367","399275","603716","688193","688136"],"gpt_icon":0},{"id":"2554075750","title":"7月25日苑东生物涨6.53%，博时研究优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2554075750","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554075750?lang=zh_cn&edition=full","pubTime":"2025-07-25 16:27","pubTimestamp":1753432027,"startTime":"0","endTime":"0","summary":"证券之星消息，7月25日苑东生物涨6.53%创60日新高，收盘报55.61元，换手率3.84%，成交量6.78万手，成交额3.72亿元。重仓苑东生物的前十大公募基金请见下表：该股最近90天内共有8家机构给出评级，买入评级5家，增持评级3家。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共19家，其中持有数量最多的公募基金为博时基金的博时研究优选LOF。博时研究优选LOF目前规模为8.62亿元，最新净值0.8874，较上一交易日上涨2.46%，近一年上涨38.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072500026001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513","160916","BK0239"],"gpt_icon":0},{"id":"2553226751","title":"单抗概念盘中拉升，百济神州-U涨0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553226751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553226751?lang=zh_cn&edition=full","pubTime":"2025-07-23 09:39","pubTimestamp":1753234793,"startTime":"0","endTime":"0","summary":"07月23日，单抗概念盘中拉升，截至09点39分，单抗概念整体指数上涨0.66%，报2657.650点。从个股上来看，该概念的成分股中，百济神州-U涨0.48%，上海医药、国药一致、华海药业涨幅居前。从资金上来看，截止发稿，单抗概念概念主力净流入为-1.40亿，其中苑东生物受到资金热捧，主力净流入348.54万；拉长时间线来看，该板块近20日主力资金净流入5384.79万。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723093953954dd1c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723093953954dd1c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0201","600521","688235","BK0070","BK0028","688513","BK0188","BK0239","BK0185","BK0012"],"gpt_icon":0},{"id":"2553625559","title":"苑东生物：股东拟询价转让336.95万股 占公司总股本的1.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553625559","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553625559?lang=zh_cn&edition=full","pubTime":"2025-07-22 20:21","pubTimestamp":1753186877,"startTime":"0","endTime":"0","summary":"苑东生物公告，成都楠苑投资合伙企业（有限合伙）、成都竹苑投资合伙企业（有限合伙）、成都菊苑投资合伙企业（有限合伙）计划参与公司首发前股东询价转让，拟转让股份总数为336.95万股，占公司总股本的1.91%。本次询价转让为非公开转让，受让方通过询价转让受让的股份在受让后6个月内不得转让。受让方为具备相应定价能力和风险承受能力的机构投资者。转让原因为自身资金需求，价格下限不低于发送认购邀请书之日（2025年7月22日）前20个交易日股票交易均价的70%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/22202151897938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2553283390","title":"单抗概念盘中拉升，百奥泰涨10.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553283390","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553283390?lang=zh_cn&edition=full","pubTime":"2025-07-22 10:02","pubTimestamp":1753149767,"startTime":"0","endTime":"0","summary":"07月22日，单抗概念盘中拉升，截至10点02分，单抗概念整体指数上涨2.07%，报2720.500点。从个股上来看，该概念的成分股中，百奥泰涨10.17%，丽珠集团、苑东生物等5只股涨幅超过5%。从资金上来看，截止发稿，单抗概念概念主力净流入为2.39亿，其中恒瑞医药受到资金热捧，主力净流入6020.83万；拉长时间线来看，该板块近20日主力资金净流入6.67亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722100247a6b976c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722100247a6b976c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1997245094.SGD","LU1064131003.USD","BK0196","LU1328615791.USD","BK0060","LU1655091616.SGD","LU2148510915.USD","LU1969619763.USD","BK0012","LU1997244956.HKD","BK0183","688513","688177","BK0188","BK0239","LU0405327148.USD","LU2328871848.SGD","LU0405327494.USD","600276","LU1997245177.USD","LU1064130708.USD","LU2488822045.USD","LU2495084118.USD","BK0028"],"gpt_icon":0},{"id":"2552104655","title":"【重磅】苑东生物发威，首款抗肿瘤生物药1类新药来了","url":"https://stock-news.laohu8.com/highlight/detail?id=2552104655","media":"米内网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552104655?lang=zh_cn&edition=full","pubTime":"2025-07-17 16:04","pubTimestamp":1752739465,"startTime":"0","endTime":"0","summary":"精彩内容7月17日，成都苑东生物制药提交了注射用YLSH003的临床申请获得承办，该新药是公司首款抗肿瘤生物药1类新药。米内网数据显示，截至目前，#苑东生物已上市的抗肿瘤和免疫调节剂均为化学药，包括了乌苯美司胶囊、卡培他滨片、磷酸芦可替尼片、达可替尼片、阿昔替尼片、阿帕他胺片6个产品，暂无生物药获批。表1：苑东生物已获批临床的抗肿瘤和免疫调节新药情况来源：米内网数据库、公司年报","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717160909a6af3cfb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717160909a6af3cfb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688513","159839"],"gpt_icon":0},{"id":"2551817651","title":"麻醉药首仿只是“冰山一角”！起底苑东生物的超车密码","url":"https://stock-news.laohu8.com/highlight/detail?id=2551817651","media":"医药研究社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551817651?lang=zh_cn&edition=full","pubTime":"2025-07-14 20:39","pubTimestamp":1752496749,"startTime":"0","endTime":"0","summary":"据悉，近日苑东生物提交的4类仿制化药注射用磷丙泊酚二钠上市申请已获受理。多维布局下苑东生物蓄势爆发实际上，注射用磷丙泊酚二钠只是苑东生物新药布局的“冰山一角”。根据米内网数据，2024年至今，苑东生物已有十多个产品获批上市。财报显示，2025年第一季度，苑东生物实现营业总收入3.06亿元，同比下降2.97%；归母净利润6059.04万元，同比下降19.22%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714211031a44a1297&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714211031a44a1297&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2551184657","title":"苑东生物涨5.33% 创新驱动构建估值安全边际","url":"https://stock-news.laohu8.com/highlight/detail?id=2551184657","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551184657?lang=zh_cn&edition=full","pubTime":"2025-07-14 14:30","pubTimestamp":1752474654,"startTime":"0","endTime":"0","summary":"苑东生物股价大幅上涨，最新价42.11元，涨跌幅为5.33%。估值压力亦不容忽视，截至7月9日动态市盈率31.83倍显著高于板块均值，半年报窗口期前部分资金选择兑现收益。创新驱动构建估值安全边际中长期看，苑东生物的核心竞争力在于创新药与国际化双轮驱动。公司研发投入强度连续三年超20%，经营性现金流同比增长18.6%，叠加2.63倍市净率低于创新药企均值，基本面为估值修复提供支撑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714143104a4491ef0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714143104a4491ef0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2550652242","title":"苑东生物股价微跌0.79% 化学制药企业研发管线引关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2550652242","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550652242?lang=zh_cn&edition=full","pubTime":"2025-07-09 01:29","pubTimestamp":1751995758,"startTime":"0","endTime":"0","summary":"苑东生物7月8日股价报40.12元，较前一交易日下跌0.32元。当日成交量为15933手，成交金额达0.64亿元。苑东生物是一家专注于化学制药领域的创新型企业，主营业务涵盖创新药和高端仿制药的研发、生产和销售。公司产品管线涉及多个治疗领域，包括心血管系统、神经系统、抗肿瘤等。7月8日数据显示，苑东生物主力资金净流入187.54万元。公司当前总市值为70.82亿元，市盈率为29.22倍。风险提示：股市有风险，投资需谨慎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709013704953b1c50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709013704953b1c50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2548514913","title":"苑东生物闪耀2025上海CPHI，共鉴制药创新力量","url":"https://stock-news.laohu8.com/highlight/detail?id=2548514913","media":"苑东生物","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548514913?lang=zh_cn&edition=full","pubTime":"2025-07-04 13:28","pubTimestamp":1751606889,"startTime":"0","endTime":"0","summary":"据统计，展会期间苑东生物累计接待来自40余个国家的200余家客户，达成超150场深度洽谈，客户对其新产品开发效率、项目进度管控及差异化产品线布局给予高度评价。面向未来，以创新驱动全球健康事业发展对于苑东生物而言，CPHI China 2025的圆满落幕并非终点，而是新征程的起点。未来，苑东生物将继续以开放姿态拥抱合作，用创新成果回应健康需求，以患者为中心，为全球医药产业发展贡献苑东力量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704133018a4cebdff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704133018a4cebdff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2548088390","title":"苑东生物：公司未有数据管理人员口径人数统计","url":"https://stock-news.laohu8.com/highlight/detail?id=2548088390","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548088390?lang=zh_cn&edition=full","pubTime":"2025-07-01 18:30","pubTimestamp":1751365846,"startTime":"0","endTime":"0","summary":"证券之星消息，苑东生物(688513)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截至2024年底，贵公司拥有的数据管理人员数量是多少？苑东生物回复：尊敬的投资者，您好！公司高度重视推进数字化、智能化在制药产业中融合，数据管理人员分布于不同业务板块与部门发挥重要作用，目前未有“数据管理人员”口径的人数统计，公司的人员分类情况您可参见公司年度报告第四节中“员工情况”相关信息。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070100030825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2548244280","title":"苑东生物涨5.43% 拟增持股权引发技术平台关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2548244280","media":"智选洞察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548244280?lang=zh_cn&edition=full","pubTime":"2025-07-01 13:52","pubTimestamp":1751349136,"startTime":"0","endTime":"0","summary":"苑东生物股价今日表现强势，截至13点51分，最新价报43.29元，上涨5.43%。但6月30日科创50指数上涨1.54%，科技成长风格修复带动创新药板块资金关注度回升。公司6月26日公告拟以1968万元增持上海超阳股权至30.68%，其分子胶、PROTAC技术平台引发市场对管线价值重估预期，成为短期催化剂。通过参股上海超阳，公司获得11项发明专利和2条临床管线，覆盖抗肿瘤与自免疾病领域，HP001、HP002等品种临床数据披露节奏或成估值重塑关键节点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701135217a4c831c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701135217a4c831c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2547015164","title":"中国创新药能否持续让世界买单？券商分析师最新观点","url":"https://stock-news.laohu8.com/highlight/detail?id=2547015164","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547015164?lang=zh_cn&edition=full","pubTime":"2025-06-30 23:29","pubTimestamp":1751297340,"startTime":"0","endTime":"0","summary":"医药魔方统计，2025年1—5月，中国创新药企对外授权交易总金额已达455亿美元，超过2024年上半年的交易总额，创新药出海授权交易大爆发。亮眼数据的背后，是中国创新药整体水平的强势崛起。“中国创新药产业的研发、临床与生产能力，正处于与国际一线水平接轨的初始阶段。”由于BD数据不及预期，年内大涨明显的创新药企业荣昌生物股价近期大幅回调，从而带动创新药板块整体调整。华泰柏瑞恒生创新药ETF6月中旬以来一度单周下行超过8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630233154a7267585&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630233154a7267585&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600557","159992","688091","603707","600380","600080","603259","688336","600062","600420","688506","688513","600196","06160","600535","688181","688198","603127","688488","600222","688136","600645","601089","600867","688235","600276","603998","603567","688331","688321","688222","688189","600513","603087","600881","603590","688505","600721","601607","600351","600851","603229","600572","688163","688356","688117","ONC","600422","600216","600682","600521","600789","688068","688131","BK0239","600200","600998","688278","600056","688520","600079","600774","603367","688073","688166","603716","688319","605199","688177","688202","600267","688317","603456","600332"],"gpt_icon":0},{"id":"2547905674","title":"晨会纪要","url":"https://stock-news.laohu8.com/highlight/detail?id=2547905674","media":"平安证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547905674?lang=zh_cn&edition=full","pubTime":"2025-06-30 00:00","pubTimestamp":1751212800,"startTime":"0","endTime":"0","summary":"整车方面，看好在高端化方面具备明显品牌特色并具备较高盈利潜力的车企，推荐理想汽车、赛力斯、长城汽车、小米集团，推荐高分红标的宇通客车。WSTS预测全球半导体市场2025年预计以11.2%增速增至7008.74亿美元；2026年市场将再增8.5%至7607亿美元。我们认为，2025年，在AIGC和消费类下游需求向好的加持下，半导体行业将继续向好，同时我国半导体产业国产化替代进程有望进一步提速，建议关注AI+自主可控的投资机会，尤其是后续国产化替代空间较大的领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630135236979430a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630135236979430a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0014","601601","688513","LU1969619763.USD","02333","02601","BK0187","601166","BK0264","603986","603590","688120","688111","BK0196","02015","688052","BK0015","BK0028","601127","600066","82333","LI","LU1580142542.USD","09660","688720","603993","LU2460026573.USD","600660","688019","688591","LU1820825898.SGD","688458","LU1770034418.SGD","03606","688018","BK0188","03993","603893","688536","LU1781817850.SGD","LU2328871848.SGD","BK0183","688220","LU1808992512.USD","601633","688012","688332","688099","LU1146622755.USD","688608","688361","BK0012","601615","688484","688049"],"gpt_icon":0},{"id":"2547704754","title":"每周股票复盘：苑东生物（688513）2024年度ESG报告发布及股权受让关联交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2547704754","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547704754?lang=zh_cn&edition=full","pubTime":"2025-06-29 08:27","pubTimestamp":1751156829,"startTime":"0","endTime":"0","summary":"截至2025年6月27日收盘，苑东生物报收于40.7元，较上周的38.2元上涨6.54%。公司将及时关注后续交易进展并按规定履行信息披露义务。成都苑东生物制药股份有限公司于2025年6月27日收到中国证券登记结算有限责任公司上海分公司出具的《过户登记确认书》，完成了2024年限制性股票激励计划首次授予第一个归属期归属的股份登记工作。2024年5月20日，公司2023年年度股东大会审议通过了相关议案。本次归属未导致公司控股股东及实际控制人发生变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062900001474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688513","159717","BK0239"],"gpt_icon":0},{"id":"2546784761","title":"苑东生物：拟受让参股公司上海超阳部分股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2546784761","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546784761?lang=zh_cn&edition=full","pubTime":"2025-06-26 18:59","pubTimestamp":1750935593,"startTime":"0","endTime":"0","summary":"本次交易完成后，公司间接持有上海超阳的股权比例将由11.3636%增加至30.6818%，上海超阳将成为公司施加重大影响的参股公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626190000952c8b31&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626190000952c8b31&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2546786817","title":"苑东生物06月26日主力净流出636.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2546786817","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546786817?lang=zh_cn&edition=full","pubTime":"2025-06-26 15:21","pubTimestamp":1750922492,"startTime":"0","endTime":"0","summary":"06月26日, 苑东生物股价跌0.28%，报收39.30元，成交金额1.0亿元，换手率1.50%，振幅4.69%，量比1.04。苑东生物今日主力资金净流出636.5万元，上一交易日主力净流入104.4万元。|06月26日主力加仓幅度排名||#|股票简称|主力净额占比|#|欢瑞世纪|6.52%|#|华锋股份|6.02%|#|科创信息|5.98%|#|...|...|#3388|苑东生物|-0.09%|苑东生物所在的化学制药行业，今日主力净流出16.11亿元，行业排名7/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626171143a4bee33c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626171143a4bee33c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2546274419","title":"苑东生物荣登药智网中国药品研发实力系列榜单","url":"https://stock-news.laohu8.com/highlight/detail?id=2546274419","media":"苑东生物","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546274419?lang=zh_cn&edition=full","pubTime":"2025-06-26 11:33","pubTimestamp":1750908836,"startTime":"0","endTime":"0","summary":"NEWS /6月20日，药智网重磅发布《2025中国药品研发实力排行榜》系列榜单，苑东生物凭借多年来持续的科技创新和研发投入，入选\"中国化药研发实力50强\"和\"中国药品研发综合实力100强\"双榜单。药智网“2025中国药品研发实力排行榜”系列榜单，自2016年起已连续发布十届。该榜单根据企业2024年度药品受理与批准数量、药企研发投入、专利数量及企业历史药品研发排行榜得分等分项进行综合评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626114118a4be6a4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626114118a4be6a4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688513"],"gpt_icon":0},{"id":"2545849280","title":"苑东生物06月23日主力净流入1382.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2545849280","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545849280?lang=zh_cn&edition=full","pubTime":"2025-06-23 15:21","pubTimestamp":1750663278,"startTime":"0","endTime":"0","summary":"06月23日, 苑东生物股价涨6.13%，报收40.54元，成交金额1.6亿元，换手率2.35%，振幅8.64%，量比1.43。苑东生物今日主力资金净流入1382.8万元，上一交易日主力净流出94.9万元。该股近5个交易日下跌6.31%，主力资金累计净流出1779.9万元；近20日主力资金累计净流出1.4亿元，其中净流出天数为17日。|06月23日主力加仓幅度排名||#|股票简称|主力净额占比|#|逸豪新材|8.98%|#|大为股份|7.79%|#|C新恒汇|7.30%|#|...|...|#525|苑东生物|0.19%|苑东生物所在的化学制药行业，今日主力净流入11.39亿元，行业排名2/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623171059a4b8984a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623171059a4b8984a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688513","BK0239"],"gpt_icon":0},{"id":"2544414967","title":"苑东生物：公司十分重视信息化在企业发展中的重要作用","url":"https://stock-news.laohu8.com/highlight/detail?id=2544414967","media":"证星董秘互动","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544414967?lang=zh_cn&edition=full","pubTime":"2025-06-20 16:00","pubTimestamp":1750406446,"startTime":"0","endTime":"0","summary":"证券之星消息，苑东生物(688513)06月20日在投资者关系平台上答复投资者关心的问题。投资者：请问贵公司2021至2023年间信息化投入大约为多少万元？苑东生物董秘：尊敬的投资者，您好。公司十分重视信息化在企业发展中的重要作用，根据生产经营需要，推进数字化、智能化在制药产业中融合，让数据管理建设成为推动公司战略实现的重要抓手，推动药品研产和信息化技术深度融合，实现药品研产数字化智能管理。相关事项的信息请以公司发布的定期报告为准，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025062016060195247200&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025062016060195247200&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688513"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753587280249,"stockEarnings":[{"period":"1week","weight":0.2432},{"period":"1month","weight":0.4111},{"period":"3month","weight":0.6429},{"period":"6month","weight":0.8215},{"period":"1year","weight":0.831},{"period":"ytd","weight":0.8632}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0398},{"period":"3month","weight":0.0906},{"period":"6month","weight":0.1048},{"period":"1year","weight":0.2449},{"period":"ytd","weight":0.0722}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都苑东生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7091人(较上一季度增加10.71%)","perCapita":"24895股","listingDate":"2020-09-02","address":"四川省成都市郫都区高新区西源大道8号","registeredCapital":"17653万元","survey":"　　成都苑东生物制药股份有限公司的主营业务是化学原料药、高端化学药品及生物药品研发、生产、销售。公司的主要产品是高端化学药品、创新药、原料药。","listedPrice":44.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"苑东生物(688513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供苑东生物(688513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"苑东生物,688513,苑东生物股票,苑东生物股票老虎,苑东生物股票老虎国际,苑东生物行情,苑东生物股票行情,苑东生物股价,苑东生物股市,苑东生物股票价格,苑东生物股票交易,苑东生物股票购买,苑东生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"苑东生物(688513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供苑东生物(688513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}